Receptor Bryan Roth  and Brian Krumm  for their excellent study on Molecular glues as potential GPCR therapeutics November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. Hauser Group Postdoctoral Scholar – iPSC in cardiac and endothelial cell function Protein Biochemist/Structural modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing therapeutics Their areas of focus include structural biology, protein production from Proteos, and nanoparticle characterization comprehensive approach enables Axxam to support clients worldwide in identifying and optimizing new therapeutic

Our next symposium on Structural and Molecular Insights into GPCR Function. multicolor suite for deciphering population coding of calcium and cAMP in vivo Cryo-EM advances in GPCR structure and human genetic disease Advances and challenges in cancer immunoprevention and immune interception Structural and Molecular Insights into GPCR Function Structural bioinformatics studies of serotonin, dopamine and Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD) Domain Therapeutics

only enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic Tate, New insights into GPCR coupling and dimerisation from cryo-EM structures.   Current Opinion in Structural Biology, 2023. 80 : p. 102574. 2.          Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic

receptor signaling Jiankun Lyu, Brian Shoichet, Bryan Roth, et al. for their research on AlphaFold2 structures Our symposium on Structural Insights into GPCR Activation is postponed. Mark your calendar for the GPCRs as Therapeutic Targets symposium on October 11th, 2024. GPR56, an Adhesion GPCR with Multiple Roles in Human Diseases, Current Status and Future Perspective Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator Structural

GPCRs remain one of the most prolific and fertile therapeutic drug targets. biosensors Descriptive molecular pharmacology of the δ opioid receptor (DOR): A computational study with structural protein-coupled receptor (GPCR) dynamics for receptor activation, signalling bias and allosteric modulation Structural and Molecular Insights into GPCR Function Structural Mass Spectrometry Captures Residue-Resolved Comprehensive Conformational Rearrangements of a G Protein-Coupled Receptor Influence of the Water Model on the Structure

We have postponed our symposium on Structural Insights into GPCR Activation to a later date. Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic and Molecular Insights into GPCR Function Membrane mimetic-dependence of GPCR energy landscapes Structural

Modeling tools to understand how restricted diffusion  in tissues like tumors slows offset and improves therapeutic In structured, diffusion-restricted environments (e.g. brain, tumors), drugs don't just leave slowly; drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic

Brian Krumm and Bryan Roth studied CryoEM structures of adhesion in GPCR CD97, filling gaps. Adhesion GPCRs CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps GPCR Activation enhance GPCR production in E. coli-based cell-free and whole cell expression systems A high-throughput structural identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy Industry News OMass Therapeutics (ANDA) Litigation PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics

Watch Episode 171 What happens when your protein has no known ligands, no structure, and very little Their structures are hard to determine experimentally due to poor expression and the volatility of odorant Enter AlphaFold: Predicting the “Face” of a Receptor When Alessandro began his PhD, structural models —Alessandro Nicoli For the first time, researchers had a reliable set of predicted structures to work “When they released the first structure of the odorant receptors… AlphaFold already had it, without any

tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic We will discuss the historic context of pepducin development for each receptor, as well as the structural , signaling, pathophysiologic consequences, and therapeutic potential for each pepducin class."

Our next symposium on Structural and Molecular Insights into GPCR Function is scheduled for June 7th. cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics

synaptic depression in dorsolateral striatum of adult male mice Methods & Updates in GPCR Research RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges Structural and Molecular Insights into GPCR Function Structural perspectives on chemokine receptors Industry News Exscientia Appoints

their appearance on the (illicit) drug market, e.g. as new psychoactive substances, their potential therapeutic This group of substances demonstrates a broad structural variety, leading to insufficiently described structure-activity relationships, hence illustrating the need for better functional characterization

Sexton et al. for their job on Cryo-EM Structure of the Human Amylin 1 Receptor in Complex with CGRP GPCR Symposia Join us on June 7th for our next symposium on Structural and Molecular Insights into GPCR , mechanisms, and drug discovery Frizzleds act as dynamic pharmacological entities Structural and Molecular into GPCR Function Molecular insights into G protein coupling specificity at a class A GPCR Cryo-EM Structure Industry News Monash University retains its N° 2 global ranking for Pharmacy and Pharmacology Addex Therapeutics

Despite its therapeutic potential, CB2 pharmacology remains difficult to interrogate with confidence. This dataset highlights how HCS can be used both to triage compound series and to extract quantitative structure–affinity For cannabinoid chemistry programs—where small structural shifts can significantly alter receptor preference or signaling bias—access to live-cell binding information can sharpen structure–activity relationships Three-dimensional quantitative structure–selectivity relationships analysis guided rational design of

The models use a variety of data for the input, including amino acid sequences or structural data (from Mutations: ML methods can determine stabilising mutations that enable structure determination and can even where no similar structure is known. 4. revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively activate therapeutically analyzing drug-target interactions and disease pathways, AI can identify potential candidates that may have therapeutic

Function and structure of bradykinin receptor 2 for drug discovery. Structural and Molecular Insights into GPCR Function The activation mechanism and antibody binding mode Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in Industry News Design Pharmaceuticals has a new website Confo Therapeutics Announces Global Licensing Antiverse raises €2.8M for its computational antibody drug discovery platform Antiverse identifies therapeutic

MCF7 breast cancer cells Reviews, GPCRs, and more The multifaceted functions of β-arrestins and their therapeutic bodies as chemical signals for the immune system AI-driven GPCR analysis, engineering, and targeting Structural and Molecular Insights into GPCR Function Characterizing conformational states in GPCR structures using Biotechnology will be presenting at the OBIO 2024 Investment Summit X-rays to AlphaFold: the future structure 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs NEW Senior Researcher in Structural

Why This Matters GPCR research demands integration — pharmacology, structural biology, signaling pathways A shared environment lowers friction between these specialties, making innovation structurally inevitable Engineering Collaboration: The Monash Lab Model Traditional academic labs mirror feudal structures. The structure you train in often matters more than the experiment you start with. Monash turned structure itself into a collaboration tool.

into the Classified GPCR News from February 26th to March 3rd, 2024 Adhesion GPCRs The repertoire and structure variants assembled from publicly available deep-sequenced human samples GPCR Activation and Signaling Structure-guided and drug discovery in endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic cadherin G protein-coupled receptors that bind cry toxins of Bacillus thuringiensis Industry News Domain Therapeutics

Structural and Molecular Insights into GPCR Function Structural and dynamic insights into supra-physiological Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide-Target Interactions. Structural and Molecular Determinants for Isoform Bias at Human Histamine H3 Receptor Isoforms. Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

GPCR Activation and Signaling New simulation insights on the structural transition mechanism of Bovine Structural and Molecular Insights into GPCR Function Thermodynamic architecture and conformational plasticity Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide-Target Interactions. Cryo-EM structures of orphan GPR21 signaling complexes. Foundation is awarding DKK 174 million in grants to seven ‘mind-bending’ research collaborations GPCR Therapeutics

Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets. Structural and Molecular Insights into GPCR Function Structural view of G protein-coupled receptor signaling Cryo-EM structure of orphan G protein-coupled receptor GPR21. Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318 GPCR Therapeutics interest’ Addex Strategic Partner Completes Enrollment In Adx71149 Epilepsy Phase 2 Study Part 1 Domain Therapeutics

The LK30/ADGRL3 complex structure revealed that the LK30 binding site on ADGRL3 overlaps with the binding using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics

Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Structural and Molecular Insights into GPCR Function Structure-based design of novel melanin-concentrating Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics

drug discovery; new strategies for inflammatory disease treatment; growth strategies from Tectonic Therapeutics and GPCR signaling in cancer at CRCM Must-read publications : AlphaFold3 benchmarking for GPCRs; new structural This misunderstanding leads to: Inefficient structure-activity relationship (SAR) cycles Wasted optimization

beta-arrestin coupling and intracellular trafficking of metabotropic glutamate receptor homo- and heterodimers Structural protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism GPCR Binders, Drugs, and more Design and structural impact of different detergents and nanodiscs on the A2A adenosine receptor Reviews, GPCRs, and more Structure Muscarinic Agonist Candidates in Phase 1 Clinical Studies AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics

Here, we review how nanobodies have been adopted to elucidate the structure, pharmacology, and signaling nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic

of both CBRs.[4–8] A key challenge in CBR modulator development is separating the therapeutic effects Chemical structure of [3H-CP-55940]. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Crystal Structure of the Human Cannabinoid Receptor CB1. Crystal Structure of the Human Cannabinoid Receptor CB2.